Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSB11022 versus EU-approved Humira in moderate to severe chronic plaque psoriasis
2015-003287-37Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing MSB11022 with Humira (2 arms). Primary endpoint: PASI 75 response. Started Jan 2016; status: completed.
02
Drugs
idacioadalimumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2015-003287-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003287-37.